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ABSTRACT: CD34+ hematopoietic progenitor cells have been shown to be susceptible to HIV-1 infection, possibly due to a low-level expression
of CXCR4, a coreceptor for HIV-1 entry. Given these observations, we have explored the impact of forskolin on cell surface expression of CXCR4
in a cell line model (TF-1). The elevation of intracellular cyclic adenosine monophosphate (cAMP) by forskolin through adenylyl cyclase (AC)
resulted in transcriptional upregulation of CXCR4 with a concomitant increase in replication of the CXCR4-utilizing HIV-1 strain IIIB. Transient
expression analyses also demonstrated an increase in CXCR4-, CCR5-, and CXCR4-/CCR5-utilizing HIV-1 (LAI, YU2, and 89.6, respectively)
promoter activity. Studies also implicated the protein kinase A (PKA) pathway and the downstream transcription factor CREB-1 in interfacing with
cAMP response elements located in the CXCR4 and viral promoter. These observations suggest that the cAMP signaling pathway may serve as
a regulator of CXCR4 levels and concomitantly of HIV-1 replication in bone marrow (BM) progenitor cells.
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Introduction

In humans, active HIV-1 replication in the bone marrow
(BM) has been suggested based on reports that the viral load
was very similar to the viral load in the blood, in terms of both
cell-free1 and cell-associated virus.2 Within BM cell subpopulations, CD34+ hematopoietic progenitor cells express the
HIV-1 receptor CD4 and low levels of the coreceptor
CXCR43 and have been reported to be susceptible to HIV-1
infection in vitro with varying efficiency.4,5 Several investigators have shown that receptor and coreceptor expression correlates with the susceptibility of progenitor cells to HIV-1.4,6–9
Therefore, it is likely that physiological events that elevate
levels of CXCR4 facilitate infection of progenitor cells by
increasing the net availability of the coreceptor at the cell surface. It has been reported that cyclic adenosine monophosphate (cAMP)-dependent upregulation of CXCR4 in human
T-lymphocytes is mediated by a cAMP-responsive element
(CRE) in the 5′ untranslated region (UTR) of its promoter.10
Therefore, it was of interest to determine whether a similar
cAMP induction would augment CXCR4 levels and HIV-1
infection in BM progenitor cells using quantitative real-time
polymerase chain reaction (qRT-PCR) and in vitro viral
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replication assays. The specific adenylyl cyclase (AC) activator
forskolin was used to augment intracellular cAMP levels in
the CD34+CD4+CXCR4+ human BM progenitor cell line
TF-1. Interestingly, we have previously identified a CRE
sequence upstream of the transcription start site in the
U3 region of the HIV-1 promoter (designated the long
terminal repeat [LTR]), and this cis–acting element
(TGCTGACATCGAGC)11 was shown to interface with
many members of the ATF (activating transcription factor)/
CREB (cAMP response element binding protein) family
of transcription factors. We also investigated the effects of
cAMP accumulation on transcription driven by the LAI (X4-),
YU2 (R5-), and 89.6 (X4/R5-) HIV-1 LTRs in TF-1 cells
using a transient expression system. Electrophoretic mobility
shift (EMS) assays were performed to identify the presence of
CREB-1, the primary cAMP-responsive transcriptional activator,12 in molecular complexes interacting with these CREs.
The contribution of CREB-1 in mediating the stimulatory
effects of cAMP on CXCR4 and HIV-1 LTR activity was
also examined. Because protein kinase A (PKA) has been
identified as the primary effector of CREB-1 activation in
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TF-1 cells, its role in facilitating cAMP-mediated effects was
also studied. Based on these results, it was hypothesized that
the cAMP-PKA-CREB-1 pathway represents a common
underlying mechanism involved in upregulating HIV-1
LTR-directed transcription and CXCR4 expression in BM
progenitor cells, resulting in increased HIV-1 infection.

Materials and methods
Reagents
Forskolin (Sigma-Aldrich), a diterpene obtained from Coleus
forskohlii, was used to elevate intracellular cAMP concentrations in TF-1 cells. The PKA-specific inhibitor H-89 was also
obtained from Sigma-Aldrich. Lysis buffers for nuclear extract
preparation were treated with Protease Inhibitor Cocktail Set
III and Phosphatase Inhibitor Cocktail Set II, which were
obtained from Calbiochem. Total cellular RNA for TaqMan
qRT-PCR was prepared from TF-1 cells using TRI Reagent
(Sigma-Aldrich).

Cell culture and treatment procedures
The TF-1 CD34+CD38+ cell line (American Type Culture
Collection [ATCC]) was grown in Roswell Park Memorial
Institute (RPMI) 1640 medium (ATCC) supplemented with
10% heat-inactivated fetal bovine serum (HyClone), penicillin
(100 U/mL), streptomycin (100 µg/mL), and recombinant
human granulocyte/macrophage colony-stimulating factor (2
ng/mL; eBioscience) and maintained at 37°C in 5% CO2 at
90% relative humidity.

Cloning and site-directed mutagenesis
The HIV-1 LAI, YU2, and 89.6 LTRs were cloned into
the pGL3-Basic vector (Promega) with the firefly luciferase
(luc) gene. The LAI-LTR-Luc, YU2-LTR-Luc, and 89.6
LTR-Luc reporter constructs have been described previously.13,14 Site-directed mutagenesis was performed using
the QuikChange mutagenesis procedure (Stratagene) on all
three HIV-1 LTR-Luc reporter vectors to incorporate a TG
mutation in the ATF/CREB site that is reported to exhibit a
knockout phenotype with respect to binding CREB-1 (Santa
Cruz Biotechnologies). The following primers were used
for site-directed mutagenesis: LAI-LTR (5′-CAA-GAACTG-CTG-TGA-TCG-AGC-TTG-CT-3′),YU2-LTR(5′-CAA-GAA-CTGATG-TGC-TCG-AGC-TTT-CT-3′), and 89.6 LTR
( 5 ′ - A C T - G A A - C T G - C T G -T G A - C T G - A G C TAT-CT-3′). Sequences were confirmed and analyzed using
Lasergene software (DNASTAR, Inc.).

Transient transfections and expression analyses
TF-1 cells (2 × 106) were transiently transfected with
the HIV-1 parental or mutated TG firefly luciferase-LTR
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constructs (1 µg) in conjunction with the pRL-TK Renilla
luciferase (Promega) internal control vector (50 ng) or a combination of wild-type luciferase-LTR constructs, pRL-TK, and
CREB-133/KCREB vectors (Clontech Laboratories, Inc.)
using the Amaxa Nucleofector System T procedure (Amaxa).
After transfection, cells were placed in new media and allowed
to recover for an hour. Cells were then either left untreated for
24 hours or pretreated with H-89 (10 µm) for 1 hour followed
by forskolin stimulation (100 µm) for 24 hours or were treated
with forskolin alone. Cell extracts were harvested and assayed
using the Dual-Luciferase Assay procedure as described by the
manufacturer (Promega). Firefly luminescence was normalized
to Renilla luminescence to control for variations in transfection
efficiency. Error bars indicate the standard deviation of the
results obtained from three independent experiments.

Isolation of RNA and qRT-PCR
TF-1 cells were serum starved for 1 hour and subsequently
total RNA was isolated from forskolin (100 µm)-treated cells
every 3 hours for 24 hours using TRI reagent. To confirm the
role of PKA in cAMP-mediated stimulation of CXCR4,
cells were pretreated with H-89 (10 µm) for one hour followed by forskolin treatment for nine hours and total RNA
extraction. To implicate CREB-1 in mediating cAMPinduced CXCR4 transcription, cells were transfected with
CREB-133/KCREB constructs as indicated earlier, treated
with forskolin (100 µm) for nine hours following recovery,
and the total RNA was isolated. Reverse transcription was
performed using the SuperScript III First-Strand Synthesis
System (Invitrogen) on 2 µg of total RNA per sample. qRTPCR was performed on cDNA samples using TaqMan
Universal PCR Master Mix and gene expression primer/
probe assays (Applied Biosystems, Inc.) for CXCR4 and for
human large ribosomal protein (RPLPO), which was examined as normalization control. Augmentation of mRNA levels in treated samples was analyzed as fold over untreated
(calibrator) on an ABI 7300 Thermocycler (Applied
Biosystems) and expressed on a linear scale. All samples were
assayed in triplicate.

Nuclear extract preparation and EMS assays
Large-scale nuclear extracts were prepared from forskolintreated (100 µm) TF-1 cells as described.15 Briefly, low passage
number, exponentially growing cells (0.5 × 106/mL) were collected by centrifugation, washed with cold phosphate-buffered
saline (PBS; CellGro), and lysed in ice-cold lysis buffer A by
homogenizing in a Dounce homogenizer. After centrifugation,
the supernatant was discarded, and the nuclear pellet was again
lysed in chilled lysis buffer C by homogenization. After vortexing for 30 minutes at 4°C, centrifugation (14,000 rpm) was
performed to collect the supernatant. This was dialyzed
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overnight at 4°C in dialysis buffer, and the concentration of
protein was determined using the bicinchoninic acid (BCA)
protein assay procedure from Pierce ECL. Complementary
single-stranded DNA oligonucleotides (corresponding to
either parental or mutated TG CRE sequences in LAI, YU2,
and 89.6 LTRs or CXCR4 5′ UTRs) were obtained from IDT
Integrated DNA Technologies. After purification of these
probes by butanol extraction and ethanol precipitation, they
were annealed by heating at 100°C for 5 minutes and slowly
cooling to room temperature. Probes were 5′-end labeled using
T4 DNA kinase (Promega) and [γ-32P] adenosine triphosphate (ATP) at 37°C. Labeled probes (75,000 cpm/lane) were
incubated with 2 µg of nonspecific DNA (poly(dI-dC) Roche)
and 12 µg of forskolin-treated nuclear extract at 30°C for 15
minutes. Supershift analyses were performed by incubation of
the complexes for another 15 minutes with CREB-1-specific
antibody (sc-186x; Santa Cruz Biotechnologies) or an isotype-matched control antibody (Santa Cruz Biotechnologies).
DNA–protein complexes were resolved on 5% nondenaturing
polyacrylamide gels at 200 V at 4°C for approximately three
hours. Gels were dried at 80°C for one hour and subjected to
autoradiography.

HIV-1 p24 ELISA
Cells were seeded into 12-well plates at a density of 0.5 × 106
cells/mL and incubated for 24 hours in the absence or presence
of forskolin (100 µm). Cells were then recounted and seeded at
a concentration of 1 × 106 cells/mL/well. This was followed by
exposure to the CXCR4-utilizing HIV-1 IIIB strain at a titer
of 105 TCID50 (50% tissue culture infective dose) (Advanced
Biotechnologies, Inc.). After 2 hours, cells were washed with 1
× PBS, resuspended in fresh RPMI 1640 media and reseeded
in 12-well plates for 24 hours. Supernatant was collected
and assayed for HIV-1 p24 core antigen using an Alliance
p24 enzyme-linked immunosorbent assay ELISA procedure
(Perkin Elmer). All samples were assayed in triplicate.

Results
Identification of CREs in the HIV-1 LTR and
CXCR4 5′ UTR
The LAI, YU2, and 89.6 HIV-1 LTR sequences were obtained
from the Los Alamos Sequence Database (GenBank accession
numbers X01762, M93258.1, and U39362.2, respectively). The
CXCR4 promoter-5′ UTR sequence was previously published
(GenBank accession ID AJ224869.1).16 Analysis of these
sequences using the online transcription factor binding site
software Match from the TRANSFAC 7 public database
(www.gene-regulation.com) identified the presence of a single
CRE in the entire CXCR4 promoter-5′ UTR (+23 to +30) and
in the HIV-1 LTR located upstream of the transcription start
site (−118 to −127) by adopting a stringent cutoff ratio (matrix
similarity = 0.8, core similarity = 0.85) (Figure 1A).
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Effects of intracellular cAMP augmentation on
LTR-directed transcription
Forskolin, a diterpene obtained from C. forskohlii, is a potent
and specific activator of AC and was used to elevate intracellular cAMP levels in TF-1 cells. Transient transfection assays
were utilized to measure LTR-driven firefly luciferase gene
expression as a direct measure of HIV-1 LTR activation.
Titration of transfected TF-1 cells with increasing concentrations of forskolin exhibited a dose-dependent increase in
HIV-1 LAI, YU2, and 89.6 LTR activity. After the results were
normalized to Renilla luciferase expression and plotted as fold
over untreated samples, it was apparent that the HIV-1 LAILTR was the most inducible (6.2-fold), the YU2-LTR was
intermediate (2.9-fold), and the 89.6 LTR was the least (1.9fold) (Figure 1B). This differential responsiveness was proposed to be a reflection of the variation in the genetic sequence
of the respective CREs specifically and the LTR in general.
Site-directed mutagenesis of the HIV-1 LAI-, YU2-, and
89.6 LTR-luc constructs to incorporate an AC to TG mutation
in the first half of the CRE site in conjunction with transient
transfections exhibited an abrogation in activity of these LTRs
in response to forskolin. After the results were normalized to
Renilla luciferase expression and compared with basal LTR
activity, the fold change of 100 µm forskolin-stimulated parental LTR-luc levels (LAI, 6.1; YU2, 2.9; 89.6, 1.8) and forskolin-stimulated TG LAI-LTR (1.17), YU2-LTR (0.49), and
89.6 LTR (0.69) were plotted that showed that LAI and YU2
activity was diminished most in comparison with 89.6 (Figure
1C), reiterating the absolute requirement for the CRE site for
facilitating cAMP-induced LTR-directed transcription.

Kinetics of cAMP-induced CXCR4 transcription
in TF-1 cells
qRT-PCR assays were performed to study the regulation of
CXCR4 transcription in response to enhanced cAMP levels
(Figure 1D). Kinetics revealed a biphasic curve, wherein transcript levels always remained elevated and returned close to the
untreated threshold level only at 24 hours after forskolin stimulation. The amplitude of the curve was observed at 6–9 hours
(4-fold increase), with transcript levels declining at 15 hours
(1.92-fold). Subsequently, a smaller peak was observed at
18 hours (2.8-fold). These results suggest functional significance of the CRE with respect to mediating cAMP-induced
CXCR4 transcription. The biphasic nature of the response to
forskolin is a likely outcome of the kinetics and dynamics relative to the interaction of cognate transcription factors with the
LTR-specific CRE.

Binding of CREB-1 to identified CREs in vitro in
TF-1 cells
To analyze the molecular basis of cAMP-induced transcription
mediated by the CREs in HIV-1 and CXCR4 promoter/UTR,
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Figure 1. Forskolin induces transcriptional activation of HIV-1 LTR and upregulation of CXCR4. (A) The molecular sequence of CREs in the LTR of
reference HIV-1 strains and in the 5′ UTR of the CXCR4 gene. TRANSFAC analysis identifies the presence of a lone CRE in the CXCR4 promoter-5′ UTR
and the HIV-1 LTRs. The sequences are compared with a classical consensus CRE in the T-lymphocyte SH2D2A promoter, and the variant base pairs are
marked in red. (B) With forskolin stimulation (the range of concentrations included 0, 10, 25, 50, 75, and 100 µm), the HIV-1 LTRs are activated and drive
luciferase gene expression to different extents. The LAI-LTR was the most inducible (6.2-fold), followed by the YU2-LTR (2.9-fold) and the 89.6 LTR
(1.9-fold). (C) After site-directed mutagenesis of LTR-luc constructs, the activity of 100 µm forskolin-stimulated TG LAI-LTR, YU2-LTR, and 89.6 LTR was
reduced by 81%, 83%, and 64%, respectively. (D) The biphasic curve of CXCR4 transcription in response to 100 µm forskolin is characterized by an initial
peak at 6–9 hours (4-fold upregulation) followed by a trough at 15 hours (1.92-fold upregulation) and a smaller peak at 18 hours (2.8-fold upregulation)
after stimulation. Although transcript levels declined at 15 hours, they remained elevated in comparison with untreated samples. Results are normalized to
RPLPO expression and expressed in linear scale as fold over untreated. Asterisks indicate significance of P < 0.05 using Student’s t–test.

EMS assays were performed to detect the presence of the transcription factor CREB-1 in complexes formed between forskolin-stimulated TF-1 nuclear extracts and radiolabeled parental
and TG-mutated oligonucleotides (Figure 2). Compared with
the “probe-only” reaction (lane 1), a specific DNA–protein
complex was detected in the case of (A) LAI, (B) YU2, (C) 89.6,
and (D) CXCR4 parental CRE probes (lane 2). This complex
consisted of three distinct bands (asterisk) that exhibited either
abrogation (Figure 2B and C) or a combination of both abrogation and supershift (Figure 2A and D) when the reaction was
incubated with a CREB-1-specific antibody (lane 4). Addition
of an isotype antibody did not affect the complex (lane 3). The
upper two bands likely represent the 43-kDa ubiquitous phosphorylated CREB-1-α,Δ activator isoforms,12 whereas the
lower band is most likely the homologous family member phosphorylated ATF-1. Incubation with mutant TG oligonucleotides prevented the formation of the CREB-1 complex,
indicating the likely involvement of CREB-1 in binding and
activation of the identified CREs.

Involvement of CREB-1 in CXCR4 and HIV-1
LTR-directed transcription in TF-1 cells
Transient transfection assays with dominant-negative
CREB-1 constructs were employed to definitively implicate

CREB-1 in cAMP-induced HIV-1 LTR activation. The
KCREB construct (pKCREB) encodes a form of CREB-1
with mutations in its DNA-binding domain. The inability to
bind CRE results in mutant CREB-1 acting as a dominantnegative repressor, blocking cAMP-induced transcription.
The CREB-133 construct (pCREB-133) also encodes a
mutated form of CREB, preventing Ser133 CREB-1 phosphorylation required for transactivation, thereby blocking
cAMP-induced transcription.
In comparison with forskolin-stimulated cells transfected
with parental LTR-luc constructs and empty vector, cells transfected with LTR-luc and CREB-133 or KCREB constructs
exhibited diminution in firefly luciferase expression (Figure 3A).
In the case of LAI, absolute expression decreased from 1 (arbitrarily set for LAI-LTR-luc) to 0.27 (LAI-LTR-luc + KCREB)
and 0.32 (LAI-LTR-luc + CREB-133). In the case of YU2,
absolute expression decreased from 1 (arbitrarily set for YU2LTR-luc) to 0.68 (YU2-LTR-luc + KCREB) and 0.56 (YU2LTR-luc + CREB-133). In the case of 89.6, absolute expression
decreased from 1 (arbitrarily set for 89.6 LTR-luc) to 0.38 (89.6
LTR-luc + KCREB) and 0.54 (89.6 LTR-luc + CREB-133).
As observed in Figure 1 with TG-mutated CREs, the LAI-LTR
is the most susceptible LTR with respect to inhibition by the
dominant-negative CREB-1. However, in contrast to earlier
observations, it is unclear why YU2 is less susceptible to
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Figure 2. CREB-1 is present in the DNA–protein complexes formed between forskolin-stimulated TF-1 nuclear extracts and identified CREs. EMS assays
performed with forskolin-stimulated TF-1 nuclear extracts and radiolabeled probes corresponding to (A) LAI, (B) YU2, (C) 89.6, and (D) CXCR4 parental
CREs revealed the presence of CREB-1 43-kDa protein in the DNA–protein complex (asterisk). Although the complex was unaffected by an isotype
antibody, it was abrogated/supershifted with a CREB-1-specific antibody. Corresponding reactions with mutant TG CRE radiolabeled oligonucleotides
exhibit the absence of the CREB-1-containing complex, suggesting that CREB-1 directly binds to parental CREs in vitro. Two other DNA–protein
complexes (double and triple asterisks) are also present and are nonspecific in nature as they remain unaffected by addition of specific antibody.

dominant-negative CREB-1 in comparison with 89.6. In the
case of LAI, the difference may be partly explained by an absolute requirement for CREB-1-CRE complex formation. We
speculate that, in the case of YU2 and 89.6, other transcription
factors and sequences adjacent to the HIV-1 LTR CRE may
also play a role in facilitating cAMP-induced LTR activation.
qRT-PCR assays with dominant-negative CREB-1 constructs were similarly used to reinforce the involvement of
CREB-1 in CXCR4 transcription. In comparison with

untransfected forskolin-treated samples, both pKCREB and
pCREB-133 transfected samples showed 2-fold decline in
levels of CXCR4 mRNA at nine hours after forskolin treatment. In the case of untransfected untreated samples, this
decline was a little more pronounced (Figure 3B). As
expected, transcription was not suppressed completely due
to the presence of endogenous CREB-1 and other transcription factor isoforms belonging to the ATF/CREB family in TF-1 cells.

6

Figure 3. cAMP-induced transcriptional activation of HIV-1 and CXCR4
promoters is specifically mediated by CREB-1. (A) In comparison with
forskolin-stimulated cells transfected with parental LTR-luc constructs
alone, cells with LTR-luc and CREB-133 or KCREB constructs exhibit
diminution in firefly luciferase expression. All firefly luciferase readings
were normalized to Renilla readings by cotransfecting cells with the
pRL-TK Renilla luciferase construct and expressed as ratios of forskolintreated to untreated samples. (B) qRT-PCR assays revealed that in
comparison with untransfected untreated and untransfected forskolintreated samples, pKCREB and pCREB-133 transfected samples showed
diminution in CXCR4 transcript levels. Results were normalized to
RPLPO expression and expressed in linear scale as fold over untreated
untransfected samples. Asterisks indicate significance of P < 0.05 using
Student’s t–test.

Effects of PKA inhibition on cAMP-induced
CXCR4 and HIV-1 LTR-directed transcription
We have previously identified PKA as a primary facilitator of
CREB-1 phosphorylation in TF-1 cells in response to cAMP
augmentation.17 Therefore, to implicate PKA as a key intermediary in the linear pathway from cAMP to CREB-1, transient
transfections and qRT-PCR experiments were performed,
assaying for firefly luciferase expression and CXCR4 mRNA
levels, respectively, in the absence or presence of the PKA
inhibitor H-89.
The forskolin-stimulated HIV-1 LAI-, YU2-, and 89.6
LTR-luc expression levels were consistent with those observed
in Figure 1B. However, the result obtained with the 89.6 LTR
was not shown to be statistically significant due to the larger
error in this experiment. In the presence of H-89 alone, there
was a marginal reduction, although not statistically significant,
with respect to basal LTR-luc levels. This is probably due to
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Figure 4. Increased cAMP-induced expression from HIV-1 and CXCR4
promoters is facilitated by PKA. (A) In comparison with untreated
samples, forskolin-stimulated cells exhibit up to a ~6-fold upregulation in
luciferase expression. This upregulation is completely inhibited by H-89
pretreatment for one hour. H-89 alone slightly diminishes basal luciferase
expression. All firefly luciferase readings were normalized to Renilla
readings by cotransfecting cells with the pRL-TK Renilla luciferase
construct and expressed as fold over untreated samples. (B) qRT-PCR
assays revealed that in comparison with untreated samples, forskolintreated samples showed a ~4.6-fold increase in CXCR4 transcript levels.
This was reduced by 50% when samples are pretreated with H-89.
Results were normalized to RPLPO expression and expressed in linear
scale as fold over untreated samples. Asterisks indicate significance of P
< 0.05 using Student’s t–test.

the fact that CREB normally plays a role in transactivating the
LTR under basal conditions. So inhibiting PKA from phosphorylating CREB under basal conditions can and probably
should still have some effect. In the case of forskolin stimulation, H-89 pretreatment completely abrogated luciferase
expression from all three HIV-1 promoters (Figure 4A). This
result confirmed the presence of PKA as the immediate effector of cAMP and suggested that PKA inhibition obliterates, in
part, downstream activation of CREB-1, thereby abolishing
cAMP-induced transcription.
Similarly, forskolin-stimulated CXCR4 mRNA levels were
consistent with those observed in Figure 1D. In comparison
with untreated samples, there was a maximum upregulation at
nine hours (4.6-fold). After pretreatment with H-89, this
upregulation was inhibited by 50% (2.3-fold). H-89 treatment
alone did not significantly affect basal CXCR4 mRNA levels
(Figure 4B). In contrast to HIV-1 LTR activity, this suggested
only partial dependence of CXCR4 transcription on PKA.
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Figure 5. Forskolin treatment enhances replication of the CXCR4utilizing HIV-1 strain IIIB in TF-1 cells. Assays for HIV-1 p24 were
performed on cellular supernatants 24 hours after infection to assess
HIV-1 IIIB replication in response to 100 µm forskolin treatment in TF-1
cells. The Y–axis denotes fold increase in p24 levels over untreated
samples. Forskolin-treated (24 hours) TF-1 cells exhibit a ~3.3-fold
increase in p24 levels.

This result was consistent with our previous experiments
wherein CREB-1 phosphorylation was not completely abolished after PKA inhibition,17 indicating the likely role of other
kinases in mediating this effect.

Effects of cAMP augmentation on HIV-1
replication in TF-1 cells
To understand if forskolin upregulation of CXCR4 in TF-1
cells resulted in increased virus infection, viral infectivity assays
were performed using a CXCR4-utilizing HIV-1 strain IIIB.
These experiments revealed an increase in replication (3.3fold) of the HIV-1 strain IIIB in response to forskolin treatment (Figure 5). Along with the results obtained from LTR
activation experiments, these results suggested that increased
CXCR4 levels might translate into increased viral entry and
subsequent replication based on the observed increase in LTRdirected transcription. Additional experiments will assess
the presence of unspliced and multiple spliced transcripts to
confirm this observation.

Discussion

Because HIV-1 has been reported to be present in the BM of
HIV-1-infected patients, it is likely that CD34+CD4+CXCR4+
BM progenitor cells are susceptible to infection by at least a
subset of HIV-1 viral strains. However, BM stromal cells produce in vivo large quantities of stromal cell-derived factor-1α
(SDF-1α), a member of the family of α-chemokines and the
only natural and endogenous ligand of CXCR4.18 CD34+CD38+
BM progenitors have also been reported to be positive for
SDF-1α.3 More importantly, SDF-1α competes with CXCR4utilizing HIV-1 with respect to binding to the coreceptor
CXCR4,19 blocking HIV-1 entry,18 and productive infection.20
Therefore, progenitors are assumed to be partially refractile to
infection in vivo. In this scenario, competition for occupation
of CXCR4 by HIV-1 can be modulated by either a decline in
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Figure 6. The cAMP-PKA-CREB-1 pathway in TF-1 cells. Forskolin
treatment enhanced intracellular cAMP levels by directly activating
membrane-bound AC. This resulted in activation of the PKA catalytic C
subunits, which diffuse into the nucleus. Once inside, they
phosphorylated CREB-1 activator isoforms. Activated CREB-1 binds to
CREs in the HIV-1 and CXCR4 promoter/5′ UTRs, thereby increasing
transcription. This may have resulted in increased surface levels of
CXCR4 and an increase in HIV-1 susceptibility.

SDF-1α production or an augmentation in levels of the coreceptor itself. Because cAMP has been reported to increase
CXCR4 transcript levels in T-lymphocytes owing to the presence of a CRE,10 it was of interest to determine whether a
similar phenomenon would apply to BM progenitor cells. This
would then relate to the potential of BM progenitor cells being
more susceptible to HIV-1 due to the increased CXCR4
expression on the cells. Secondarily once integrated in the cell
cAMP could also induce the LTR compounding the infection
by driving more viral transcription and hence replication. The
in vivo significance of this question is not lost as patients with
late-stage HIV-1 infection exhibit very high circulating levels
of prostaglandin E2,21 a natural cAMP-inducing ligand. For
our studies, the well-characterized CD4+CXCR4+ human
BM progenitor cell line TF-1 and the cAMP-enhancing
AC-activator forskolin were selected for use in the experimental design. A biphasic wave of induction was observed in
CXCR4 transcription in TF-1 cells. We also determined
whether elevated cAMP levels would affect HIV-1 promoter
activity, given that we have previously identified a CRE in the
HIV-1 LTR.11 The presence of a single CRE in the LTRs of
LAI, YU2, and 89.6 strains was detected by TRANSFAC
analyses by comparison with a consensus CRE. In addition to
the structural differences among the CREs in the LTRs of the
individual HIV-1 strains, these elements were observed to be
different from the CRE present in the CXCR4 5′ UTR. These
genetic alterations are likely to affect the responsiveness of
these genes to a cAMP stimulus due to the potential for differential recruitment of cAMP-responsive transcription factors
to CREs with different sequence variants. This possibility was
reiterated in transient transfection assays wherein the LAILTR was found to be most inducible in comparison with the
YU2 and 89.6 promoters. Moreover, the cAMP response was
found to be directly mediated by the identified CRE as apparent from site-directed mutagenesis studies. qRT-PCR and
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transfection analyses also identified PKA and the transcription
factor CREB-1 as key sequential effectors of this dual-pronged
stimulation of CXCR4 and HIV-1 LTR-mediated transcription. Finally, an observed increase in replication of CXCR4utilizing IIIB strain in forskolin-stimulated TF-1 cells
highlights the utility of these cells as a physiologically relevant
cellular model (Figure 6) for determining the effects of intracellular cAMP elevation on HIV-1 infection as well as gene
expression in progenitor cells.
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